首页|孤独症谱系障碍治疗靶点及其药物研发进展

孤独症谱系障碍治疗靶点及其药物研发进展

扫码查看
孤独症谱系障碍(autism spectrum disorder,ASD)的发病机制至今尚未明确。近年来,针对ASD病因或治疗靶点的研究逐渐增多,如干细胞疗法、微生物群-肠-脑轴、腺相关病毒基因治疗、兴奋-抑制(excitatory-inhibitory,E-I)失衡、内源性大麻素(endocannabinoid,eCB)系统及磷酸肌醇3-激酶(phosphoinositide3-kinase,PI3K)信号通路等。部分药物研发已取得初步进展,本文就ASD治疗靶点及药物研发情况进行综述。
Advances of research and development on therapeutic targets and drugs for autism spectrum disorder
The pathogenesis of autism spectrum disorder(ASD)has remained elusive.Currently there are growing researches on the etiologies or therapeutic targets of ASD,such as stem cell therapy,microbiota-gut-brain axis,adeno-associated virus gene therapy,excitatory-inhibitory(E-I)imbalance,endocannabinoid(eCB)system and phosphoinositide3-kinase(PI3K)signaling pathway,etc.Some drugs have demonstrated some promising results.This reviews summarized the latest therapeutic targets and drug R & D for ASD.

autism spectrum disordertherapeutic targetsresearch and development of drugs

冯殿伟

展开 >

天津市安定医院药剂科,天津 300222

孤独症谱系障碍 治疗靶点 药物研发

2024

中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
年,卷(期):2024.44(18)